A "second generation" platinum metallodrug effective in cancer chemotherapy that has been approved by the FDA for the treatment of ovarian cancers in 1989. Carboplatin is less toxic than the "first generation" antitumor drug, cisplatin.

 

 

IUPAC  name: cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II).